secwatch.observer — SEC 8-K summary
======================================

Issuer:     ORAGENICS INC (OGEN)
CIK:        0001174940
Form:       8-K
Filed at:   2023-02-24T23:59:59+00:00
Accession:  0001493152-23-006001
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oragenics enters $5M ATM offering with Ladenburg Thalmann; cash $11.4M, runway through Q3 2023
--------------------------------------------------------------------------------

- Entered ATM sales agreement with Ladenburg Thalmann to sell up to $5M of common stock; 3% commission.
- Cash and equivalents expected ~$11.4M as of Dec 31, 2022; sufficient to fund operations through Q3 2023.
- Reverse stock split (1-for-60) completed Jan 20, 2023; post-split shares outstanding ~2.02M.
- Plans to file IND for NT-CoV2-1 (Terra CoV-1) in US or Canada and start Phase 1 in H2 2023.
- Proceeds to fund pre-clinical development of SARS-CoV-2 vaccine and lantibiotics program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1174940/000149315223006001/0001493152-23-006001-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1174940/000149315223006001/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-006001

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer